HepaRegeniX appoints Dr. Andreas Busch as Senior Advisor
Dr. Busch will help the Company to further advance the development of MKK4 inhibition, a first-in-class treatment paradigm for liver resection and transplant.
HepaRegeniX berichtet positive Topline-Ergebnisse seiner klinischen Phase-1-Studie mit dem First-in-Class MKK4-Inhibitor HRX-0215
HRX-0215 war sicher und gut verträglich bei gesunden Freiwilligen.
HepaRegeniX reports positive topline results of its Phase 1 Clinical Trial of HRX-0215, a First-In-Class MKK4 inhibitor
HRX-0215 proved to be safe and well tolerated in healthy volunteers.
HepaRegeniX ernennt Elias Papatheodorou zum neuen Vorsitzenden des Beirats
Er folgt auf Dr. Graham Dixon, der dem HepaRegeniX Beirat seit 2017 vorstand.
HepaRegeniX appoints Elias Papatheodorou as new Chairman of the Board of Directors
He follows Dr. Graham Dixon who served as Chairman on the Board of HeparegeniX since 2017.
HepaRegeniX stellt auf zwei Fachkonferenzen wichtige Ergebnisse zu MKK4-Inhibitoren und ihrer therapeutischen Wirksamkeit vor
Neue Daten belegen therapeutisches Potenzial der MKK4-Inhibition bei fortgeschrittenen Lebererkrankungen.
HepaRegeniX to present key results on MKK4 inhibitors and their therapeutic efficacy at upcoming scientific conferences
New data supporting therapeutic potential of MKK4 inhibition in advanced liver diseases.
HepaRegeniX initiates a preclinical collaboration with the Netherlands Cancer Institute
HepaRegeniX initiates a preclinical collaboration with the Netherlands Cancer Institute to explore the potential of its 2nd MKK4 inhibitor HRX-0233 for use in cancer combination therapy.
HepaRegeniX startet präklinische Kollaboration mit dem Netherlands Cancer Institute
HepaRegeniX startet präklinische Kollaboration mit dem Netherlands Cancer Institute, um das Potenzial seines zweiten MKK4-Inhibitor HRX-0233 in der Kombinationstherapie gegen Krebs zu untersuchen
HepaRegeniX initiates first-in-man Phase 1 trial for its lead MKK4 inhibitor HRX‑0215
HRX-0215 is the first compound from the company´s small molecule-based drug discovery platform ready for clinical testing.